Melanoma is the third most common cancer in Australia, with an average of one person diagnosed every 30 minutes.

Since 2021, AGRF has been a key partner in the Zero Childhood Cancer Program (ZERO), Australia’s first precision medicine initiative for children with cancer. AGRF provides vital multi-omic sequencing data for each child, which helps inform personalised treatment plans.

AGRF is partnering with SeonixBio to support the development and clinical implementation of a genetic risk prediction test for glaucoma. Assessing genetic risk of developing glaucoma will enable individuals to monitor for symptoms and make treatment decisions.

AGRF plays a crucial role by providing genomic sequencing and analysis to patients with upcoming transplant procedures.

Epigenetics is an exciting and rapidly expanding field in biology that has garnered interest in its applications to human health. It offers a promising approach to our understanding of how environmental factors can impact gene expression and contribute to the risk of chronic conditions.